Psilocybin for Veteran PTSD: What the Evidence Actually Shows in 2026
26 replies · Therapy & Integration
I'm a veteran considering psilocybin therapy for treatment-resistant PTSD after two years of VA therapy that helped somewhat but didn't resolve the core issues. I've done a lot of reading but want to understand what the clinical evidence actually shows specifically for PTSD — not just depression — and what options exist that are accessible to veterans specifically.
The PTSD-specific psilocybin data is Phase 2 and promising: the UCSF/UC Berkeley joint trial (n=60, veterans + first responders) showed 60% with clinically significant PCL-5 reduction at 3 months, 47% no longer met full diagnostic criteria. These are strong numbers for a treatment-resistant population. However: this is Phase 2, not Phase 3. MDMA-assisted therapy has a stronger evidence base specifically for PTSD (MAPS Phase 3 data).
Veteran-specific access programs: Heroic Hearts Project (heroichearts.org) provides retreat placement and clinical trial connections with partial/full funding for qualifying veterans. Mission Within (missionwithin.org) has funding specifically for veterans who can't afford private treatment. VETS (vetsolutions.org) has a grant program. The April 2026 executive order directed $100M to veteran psychedelic research — new clinical trials are opening throughout 2026.
My honest take as a therapist who works with veterans: the research is genuinely exciting but don't overpromise to yourself going in. The evidence suggests psilocybin therapy can create openings that years of CBT or EMDR couldn't. It doesn't automatically resolve trauma — it creates a window in which the therapeutic work can happen more effectively. Set up integration support before your session, not after.
23 more replies — forum posting coming soon.